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Abstract
Background: Over the past ten years MRSA has become endemic in hospitals and is associated with
increased healthcare costs. Critically ill patients are most at risk, in part because of the number of invasive
therapies that they require in the intensive care unit (ICU). Washing with 5% tea tree oil (TTO) has been
shown to be effective in removing MRSA on the skin. However, to date, no trials have evaluated the
potential of TTO body wash to prevent MRSA colonization or infection. In addition, detecting MRSA by
usual culture methods is slow. A faster method using a PCR assay has been developed in the laboratory,
but requires evaluation in a large number of patients.
Methods/Design: This study protocol describes the design of a multicentre, phase II/III prospective
open-label randomized controlled clinical trial to evaluate whether a concentration of 5% TTO is effective
in preventing MRSA colonization in comparison with a standard body wash (Johnsons Baby Softwash) in
the ICU. In addition we will evaluate the cost-effectiveness of TTO body wash and assess the effectiveness
of the PCR assay in detecting MRSA in critically ill patients. On admission to intensive care, swabs from
the nose and groin will be taken to screen for MRSA as per current practice. Patients will be randomly
assigned to be washed with the standard body wash or TTO body wash. On discharge from the unit, swabs
will be taken again to identify whether there is a difference in MRSA colonization between the two groups.
Discussion: If TTO body wash is found to be effective, widespread implementation of such a simple
colonization prevention tool has the potential to impact on patient outcomes, healthcare resource use and
patient confidence both nationally and internationally.
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Background
Over the past ten years there has been a dramatic increase
in the number of infections caused by MRSA in several
countries, including the United Kingdom (UK) [1]; this
pathogen is now endemic in hospitals throughout the
country. It appears that although many patients begin by
being colonized, without any clinically evident infection,
between 30% and 60% of colonized critically ill patients
subsequently develop an infection syndrome attributable
to the organism [2,3]. In fact, colonization pressure
(number of MRSA carrier patient-days/total patient-days)
is a major independent predictor of MRSA infection in a
given critically ill population [4].
MRSA infection appears to be associated with greater
attributable mortality than infection with methicillin-sen-
sitive Staphylococcus aureus (MSSA), based on a recent
meta-analysis of bacteraemia outcomes [5], although this
may reflect the vulnerability of the patient population
infected by MRSA, rather than greater virulence of the
organism per se. Nevertheless, compared to MSSA, infec-
tions with MRSA demand treatment with antimicrobial
agents of greater toxicity and acquisition costs; many of
these drugs also require frequent monitoring of serum lev-
els, further adding to the total cost of therapy [1,5]. More-
over, MRSA infection is associated with prolonged length
of hospital stay, including duration of Intensive Care Unit
(ICU) stay; using data from the National Audit Office,
nosocomial infection is estimated to be associated with,
on average, 11 additional days in hospital and total costs
of 2.8 times that of uninfected patients [6-10]. Indeed,
even without progression to infection, colonized patients
require increased healthcare resource in the numerous
measures implemented to limit the spread of MRSA to
other patients. Investigators in Canada, using a cost
model, estimated the additional cost per patient episode
arising from MRSA colonization (without infection)
equivalent to £650 [11]. Applying these costs to local ICU
surveillance data, new MRSA colonization alone may add
around £65,000 per annum to cost of care in a 17-bed
ICU, aside from costs of prolonged ICU stay.
MRSA acquisition among critically ill patients represents a
particular problem. Although it is difficult to compare
data from different institutions and different countries
because of inconsistencies in surveillance approaches,
ICUs typically emerge with the highest incidence of MRSA
compared to other wards [12]. Furthermore, ICUs may
have a pivotal role in the dissemination of MRSA within
an institution [13]. Moreover, prolongation of ICU stay
attributed to MRSA infection has particular resource
implications, arising from the exceptional cost of care in
this setting [7]. Therefore, reducing the burden of MRSA
in an ICU has potential to exert tangible benefits both
within that ICU and in other clinical departments.
Clearly, an intervention which might reduce the preva-
lence of MRSA has the potential to exert an extremely
favourable impact on both patient outcomes and hospi-
talization costs.
Reducing the prevalence of MRSA among hospitalized
patients requires several, complex, interrelated interven-
tions. Fundamentally, such a strategy requires prompt
identification of colonized individuals and robust meth-
ods to reduce transmission to noncolonized patients. In
this study, we propose to address both of these require-
ments. First, in the form of a randomized clinical trial we
aim to evaluate the impact of daily washing with a 5% tea
tree (Melaleuca alternifolia) oil preparation on new MRSA
acquisition among ICU patients. Second, in the form of a
prospective observational study we aim to verify in this
setting a rapid molecular assay for the detection of MRSA,
with reference to extant culture-based methods.
Tea tree oil (TTO) is a naturally occurring chemical with
broad microbicidal activity which is known to include
MRSA [14,15]. Only a small number of clinical trials have
been conducted using preparations containing TTO.
These establish proof of concept that topical formulations
suitable for human use may eradicate MRSA skin coloni-
zation [16-18]. In a randomized controlled trial (RCT) of
TTO (4% nasal ointment and 5% body wash) compared
to routine care (nasal mupirocin and triclosan body wash)
for MRSA decolonization, 5 of 15 patients in the TTO
group compared with 2 of 15 in the routine care group
were successfully decolonized, although this difference
was nonsignificant due to small sample size [17]. In the
second published RCT for MRSA decolonization 224
patients were enrolled and received either standard treat-
ment (nasal mupirocin and chlorhexidine body wash) or
TTO (10% nasal cream and 5% body wash) [16]. Overall,
41% receiving TTO were successfully decolonized, similar
to standard care. On subanalysis, TTO was superior for
decolonization of superficial skin sites.
The utility of TTO preparations for MRSA decolonization
has not been further evaluated in robust clinical trials.
Furthermore, in spite of the laboratory and clinical evi-
dence supporting the efficacy of such preparations in
eradicating MRSA, there are no published data evaluating
the role of TTO in the prevention of MRSA acquisition.
Since TTO has proven efficacy, low toxicity and, as it is not
part of the standard therapeutic armoury, prophylactic use
does not expose a current MRSA treatment to the threat of
resistance, we propose that this would be a logical strategy
to investigate. In view of the resource implications of
MRSA colonization and infection, it is imperative that
interventions which focus on reducing these are also sub-
jected to cost-effectiveness analyses.BMC Infectious Diseases 2008, 8:161 http://www.biomedcentral.com/1471-2334/8/161
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With reference to identifying colonized patients more
promptly, we propose to verify an established in-house
MRSA PCR assay. This is an area of immense need since
the current standard of culture-based diagnosis, with a
turnaround time of 48–96 hours (depending on the
result) is suboptimal. Therefore, noncolonized patients
may be at risk of MRSA acquisition arising from exposure
to colonized (but still unidentified) patients for an unac-
ceptably long period of time. We have optimized a real-
time PCR-based assay in our laboratory which has the
potential to facilitate a same-day turnaround for MRSA
detection. The assay, however, needs to be verified using a
large number of clinical specimens from a large number
of patients, with reference to the current diagnostic stand-
ard, before it is acceptable to introduce this new test to
routine care.
Methods
Research hypotheses
The primary research hypothesis is that MRSA coloniza-
tion among critically ill patients will be reduced by daily
washing with 5% TTO body wash in comparison with a
standard body wash (Johnsons Baby Softwash). The sec-
ondary hypotheses are that 5% TTO body wash is more
cost-effective than a standard body wash (Johnsons Baby
Softwash); and that there is no difference in sensitivity
and specificity between a PCR-based assay for detection of
colonization with MRSA and the standard culture
method.
Design and setting
This multicentre phase II/III prospective, open-label, ran-
domized controlled clinical trial tests the effect of 5% TTO
body wash versus standard body wash for prevention of
MRSA colonization in critically ill adults. The study is
being undertaken in two ICUs in two Health and Social
Care Trusts (HSCT) in Northern Ireland. The Regional
Intensive Care Unit (RICU) at the Belfast HSCT is a 17-
bed intensive care unit (ICU) which receives general med-
ical and surgical patients as well as patients both from
regional specialty departments of the Royal Hospitals and
from district general hospitals requiring level 3 care. The
ICU at the South Eastern HSCT at the Ulster Hospital site
is a 10-bed critical care unit which receives general medi-
cal and surgical patients requiring level 2 and level 3 care.
Participants and sample size
All patients admitted to the ICUs during the study period
will be eligible for inclusion in the study except those
patients who fulfil the following exclusion criteria: less
than 18 years of age; known to be colonized with MRSA at
the time of admission; on admission, are judged as
unlikely to remain in the ICU for at least 48 hours; are
recruited, but whose pre-intervention MRSA screening
tests are subsequently found to be positive (by standard
culture); consent declined; and have a known sensitivity
to TTO.
The primary outcome measure is the difference in MRSA
colonization between groups at ICU discharge. The inci-
dence of MRSA colonization during ICU admission in the
study population is 13% (data obtained from the feasibil-
ity study conducted in one of the ICUs). A sample size of
1080 subjects (540 in each group) will have 80% power at
a two-tailed significance level of 0.05 to detect a clinically
significant difference of at least 40% in efficacy between
5% TTO and standard body wash. As the study will be
confined to ICU, with nursing staff administering the
study treatment, compliance will be guaranteed. Given
the intensive monitoring in ICU, we do not expect any
loss to follow-up.
Recruitment of patients, randomisation and consent
When a patient is admitted, the investigator will contact
the on-line randomization centre in the Clinical Research
Support Centre [a centre providing design, management
and coordination services for clinical trials and other stud-
ies conducted within the Health and Personal Social Serv-
ices in Northern Ireland and funded by the Research and
Development Office, Northern Ireland]. The investigator
will complete the screening form on-line and this will
generate a screening number indicating whether the
patient is randomized or excluded. The randomization
centre will provide the investigator with the allocation to
receive either intervention A or B. The investigator will
then obtain the appropriate intervention for the patient,
which will be stored on the ICU. A record of all patients
not randomized, including the reason for not being
recruited, will be maintained by the investigator.
As patients are at risk from immediate exposure to MRSA
from admission to the ICU, the success of this study will
be dependent on randomizing patients as soon as possi-
ble. Furthermore as patients will be critically ill, they will
not have the capacity to be able to give or withhold
informed consent. Delay in recruiting patients would
mean a significant proportion of patients would be
excluded. Therefore, as the intervention is low risk, we
plan to randomize patients on admission and obtain pro-
spective/retrospective consent from their legal representa-
tive as soon as possible. In addition, retrospective consent
will be obtained from the patient as soon as they are com-
petent. This approach has previously been adopted in tri-
als in the critical care setting [19-21]. In line with The
Medicines for Human Use (Clinical Trials) Regulations
2004 and to comply with the Research Governance
Framework, consenting processes will be standardised,
and reinforced via training prior to study start-up. The
planned flow of patients through the study is illustrated in
Figure 1.BMC Infectious Diseases 2008, 8:161 http://www.biomedcentral.com/1471-2334/8/161
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Participant enrolment flow diagram Figure 1
Participant enrolment flow diagram.
Not randomized 
1. Age < 18 years 
2. Colonized at time of admission 
3. Known sensitivity to TTO 
4. Unlikely to remain in ICU for 48 hours
Withdrawn 
1. Pre-intervention MRSA screening test positive
Consent 
Withdrawn 
1. Legal representative declines consent
Baseline MRSA screening 
(nasal and groin)
Randomized 
Day 0 
Eligibility assessed
5% TTO body wash  Johnsons Baby Softwash
Completed  Withdrawn  Completed Withdrawn
Primary Outcome   Study  endpoints
New MRSA colonization    Death 
(nasal and groin at discharge)  Withdrawal of consent BMC Infectious Diseases 2008, 8:161 http://www.biomedcentral.com/1471-2334/8/161
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Withdrawal from the study and the intervention
Individual patients will remain in the study until one of
the following study termination criteria is reached: death;
pre-intervention MRSA screening test is subsequently
found to be positive; unit discharge; or patient or legal
representative decline consent or request withdrawal from
the study. The intervention will be continued in partici-
pating patients until one of the following intervention ter-
mination criteria is reached: adverse effect arising from
either preparation; discharge from the unit; or MRSA col-
onization.
Outcome measures
The primary outcome measure is new MRSA colonization
during the inpatient episode in ICU, as defined by detec-
tion of MRSA by conventional culture methods in screen-
ing swabs of nose and groin, or in clinical specimens
processed by the laboratory in the course of normal clini-
cal care. This outcome measure is important as infection
is typically preceded by colonization. The definition of
colonization is clearly defined and unambiguous and it
has established resource implications.
The secondary outcome measures are as follows: cost sav-
ings per case of MRSA colonization avoided; incidence of
MRSA bacteraemia in each group; consumption of glyco-
peptide antibiotics, linezolid, rifampicin and fusidic acid;
maximum increase in sequential organ failure assessment
(SOFA) scores during inpatient episode, with reference to
admission baseline; and agreement between MRSA
screening results obtained by conventional culture and
the PCR assay under evaluation.
Ethical approval
The study will be conducted in accordance with the ethical
principles that have their origin in the Declaration of Hel-
sinki. It has been reviewed and approved by the Office for
Research Ethics Committees Northern Ireland (reference
07/NIR03/71) and has received approval from the Medi-
cines and Healthcare products Regulatory Agency (refer-
ence 22761/0008/001-0001).
The Intervention
Intervention A is a standard care body wash preparation
(Johnsons Baby Softwash). Intervention B is a proprietary
5% tea tree oil (TTO)-enriched body wash preparation,
since this formulation has proven efficacy in achieving
MRSA decolonization [16]. Patients will be randomised to
5% TTO body wash (Novabac 5% Skin Wash) or John-
sons Baby Softwash. The Novabac 5% Skin Wash contains
the active ingredient melaleuca alternifolia oil 50 mg/g.
When participants are allocated to either intervention the
nurse will have only the allocated preparation available
for the entire duration of time in the ICU that they are
enrolled in the study. A standardized washing protocol is
followed for patient hygiene in the ICUs. However, the
quantity of body wash to be applied to individual patients
is likely to be variable, depending on several factors that
cannot be easily controlled, such as body surface area. The
quantity administered therefore will be allocated to the
discretion of the nursing staff.
Risks to patients from intervention
The risk to patients associated with each intervention is
estimated to be low. This is based on data assimilated in a
recent review of the toxicity of TTO which concludes that
topical use of this agent is relatively safe and that adverse
effects are minor, self-limiting and uncommon [22]. Fur-
thermore, in a randomized controlled trial of 110 patients
who received 5% topical TTO for five days in a study of
MRSA decolonization, no participants experienced
adverse effects and no premature discontinuation was
necessary [16]. Cutaneous adverse effects appear to occur
in a significant proportion of patients only if much higher
concentrations of TTO are used [23]. Very low concentra-
tions (<0.01%) of TTO are associated with the develop-
ment of resistance to both TTO and antibiotics in MRSA
in vitro. However, as we will use 5% which kills MRSA this
does not facilitate the development of resistance. None-
theless, we will collect data on resistance of MRSA to anti-
biotics throughout the study. Adverse effects will be
monitored daily by incorporating a record of washing and
adverse events in standard nursing records. If any adverse
events occur they will be reported to the medical staff and
treated appropriately. An adverse events form will be com-
pleted. The Belfast, and South Eastern HSCTs are sponsor-
ing and providing indemnity for this study. Participant
safety and well-being are protected by implementing
standard operating procedures as set out in the Research
Governance Framework and the Medicines for Human
Use (Clinical Trials) Regulations, 2004.
Data collection methods and assessments: TTO evaluation 
and PCR verification
Data will be collected in a standardized manner across
both sites according to Standard Operating Procedures. In
both sites, patients will have screening specimens for
MRSA carriage (using conventional culture methods on
nasal and groin samples) carried out as a component of
routine care by the nurse responsible for their care on
admission to the ICU. For pragmatic reasons, duplicate
specimens for processing by the PCR assay will only be
taken in the RICU in the Belfast HSCT. All specimens will
be obtained prior to either intervention commencing and
will consist of swabs from both the nose and groin of all
patients. Patients whose admission screening is positive
by either method will be removed from the study (see
exclusion criteria).BMC Infectious Diseases 2008, 8:161 http://www.biomedcentral.com/1471-2334/8/161
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To facilitate verification of the PCR assay in the Belfast
HSCT study population, its results will be compared to the
culture results. Where there is disagreement between the
culture and PCR results both will be repeated. In instances
when the culture is persistently positive but the PCR assay
persistently negative, this will be recorded as a false-nega-
tive PCR result (assuming a true-positive culture result). In
instances when the culture result is persistently negative
but the PCR assay is persistently positive, this will be
recorded as a true-positive PCR result (assuming a false-
negative culture result). If either test is not consistently
positive or negative, it will be recorded as equivocal.
The presence of established major risk-factors for MRSA
will be recorded, so that each can be analyzed as a covari-
ate. These are:
￿ Total number of antibiotic-days during the ICU episode
[24-26].
￿ Age (blocked by 10-year intervals).
￿ Number of comorbidities
￿ Intravascular catheter-days (number of devices ×
number of days) [27,28].
￿ Length of ICU stay [28,29].
￿ Severity of illness on admission to ICU [29].
Several other MRSA risk factors exist, such as transfer from
high prevalence clinical units, multiple prior hospitaliza-
tions and residence in a nursing home. However, if partic-
ipants are culture-negative at the time of admission to
ICU, then these factors are not significant and therefore
will not be recorded.
End-of-study screening specimens will be obtained from
all participants on ICU discharge or death to identify
those patients in whom MRSA acquisition has occurred
during the inpatient episode. Additional information
regarding MRSA acquisition as a result of MRSA detection
in other clinical specimens taken as part of routine care in
the ICU will also be recorded. The time of swab collection
will be recorded.
Quantity of body wash will be determined by counting
the number of bottles used. Antibiotic consumption will
be retrieved from prospectively generated computerized
patient records. Compliance and adverse effects will be
monitored daily by incorporating a record of washing
(including time of washes) and adverse events in standard
nursing records.
Cost-effectiveness evaluation
In the cost-effectiveness analysis, the evaluation will be
performed from the perspective of the payer (i.e. the
NHS), as advocated by the National Institute for Health
and Clinical Excellence (NICE) [30], hence the evaluation
will focus on additional direct healthcare costs incurred as
a result of MRSA colonization. Collection of all resource
use data will take place continuously throughout the
study period. Patient-specific direct healthcare resource
use (such as additional ICU days, antibiotic consumption,
additional contact precautions, laboratory tests) will be
collected alongside the RCT for both control and interven-
tion groups, and supplemented with standardized unit
cost data [31]. We will also record TISS (Therapeutic Inter-
vention Scoring System) data. TISS is recognized and used
worldwide as an indicator of the amount of care invested
for a particular patient over an agreed time period. The
score is a set of selected therapeutic activities among the
many activities performed in ICUs. No attempt will be
made to quantify non-healthcare costs, costs incurred by
the patient, and costs associated with the rise of antibiotic
resistance, as this is beyond the remit of the current eval-
uation.
Schedule for assessments
Table 1 demonstrates the schedule for assessments to be
performed at given time periods. Data for the previous 24-
hours will be collected between 8 am and 10 am. The
baseline assessment serves two purposes – first to ensure
that patients recruited to the trial meet the inclusion crite-
ria, and second to obtain baseline measures. Trial specific
data will be collected in a Case Report Form for source
data verification.
Statistical analyses
Hypothesis 1: TTO evaluation
For continuously distributed outcomes, differences
between groups will be tested using independent samples
t-tests, analysis of variance (ANOVA) and analysis of cov-
ariance (ANCOVA) with transformations of variables to
normality if appropriate, or non-parametric equivalents.
Chi-square tests (or Fisher's Exact tests) will be used for
categorical variables. Major risk-factors for MRSA will be
analyzed as covariates. Efficacy of intervention will be
analysed on an intention to treat basis. A P value of ≤ 0.05
will be considered significant. A single final analysis is
planned at the end of the trial.
Hypothesis 2: Cost-effectiveness analysis
Consistent with NICE recommendations, resource use
and unit cost data will be presented separately, in £Ster-
ling (2007); discounting of costs and outcomes at 3.5%
per annum will be performed. Statistical analyses will be
performed to examine differences in costs between groups
and bootstrapping will be undertaken to allow for theBMC Infectious Diseases 2008, 8:161 http://www.biomedcentral.com/1471-2334/8/161
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skewed distribution of costs. Variability in cost-generating
events will be examined by calculating the variance/mean
ratio, and variability in costs examined by calculating the
coefficient of variation. An incremental cost-effectiveness
ratio (ICER) will be calculated, which is defined as the
change in costs over the change in effect: ICER = Δc/Δe.
The ICER (and 95% confidence ellipses) will be presented
on the cost-effectiveness plane. Uncertainty relating to the
data used in the analysis, methodological assumptions
and the need to extrapolate the data or generalize to other
settings will be addressed by decision analytic modelling
and a range sensitivity analysis performed to determine
the extent of uncertainty in point estimates.
Hypothesis 3: Verification of PCR assay
Agreement between MRSA screening results obtained by
the PCR assay versus conventional culture with reference
to the definitions of true and false positivity above will be
evaluated, to estimate the sensitivity, specificity, positive
and negative predictive values of the PCR assay in this
population.
Data Management and monitoring procedures
The study team will undertake the clinical trial in accord-
ance with Good Clinical Practice. The data collected will
be transcribed on to an electronic Case Report Form main-
tained by staff at the Clinical Research Support Centre.
Site monitoring visits will involve source data verification.
Submitted data will be anonymised, reviewed for com-
pleteness and consistency and then entered on a database.
Data will be stored securely against unauthorised manip-
ulation and accidental loss. Desktop security will be main-
tained through user names and frequently updated
passwords and back up procedures. All essential docu-
ments and trial records will be archived in conformance
with the applicable regulatory requirements and access to
these archives will be restricted to authorised personnel.
Safety and well being of study participants
Participant safety and well-being are protected by imple-
mentation of the sponsoring organisations' standard
operating procedures as set out in the Research Govern-
ance Framework and The Medicines for Human Use
(Clinical Trials) Regulations 2004. The research will be
managed through a dedicated Research Management Sys-
tem. The conditional use of this system ensures compli-
ance with sponsor and care/employing organisation
responsibilities. The system utilises a risk assessment exer-
cise within its study development phase and directs the
focus and frequency of monitoring proportionate to study
Table 1: Timing of assessments
Baseline Day 1 to n Day n (ICU discharge) Hospital discharge
Inclusion/exclusion criteria *
Demographics *
APACHE II score *
SOFA score * * *
TISS score * *
Isolation * * *
Steroid use * * *
Antibiotic list * * *
Invasive devices list * * *
Colonisation data * * *
Infection data * * *
No. of cultures sent to laboratory * * *
Adverse events * *
Whether neighbouring patient has MRSA * *
Standard groin swab * *
Standard nasal swab * *
PCR groin swab (Belfast HSCT) *
PCR nasal swab (Belfast HSCT) *
Details of wash * * *
No of body wash bottles used * *
Duration of ventilation *
ICU length of stay *
ICU survival *
Hospital length of stay *
Hospital survival *
Discharge location *
APACHE II – Acute Physiological & Chronic Health Evaluation II; HSCT – Health and Social Care Trust; ICU – Intensive Care Unit; MRSA – 
Methicillin-resistant Staphylococcus aureus; PCR – Polymerase chain reaction; SOFA – Sequential Organ Failure Assessment; TISS – Therapeutic 
Intervention Scoring System;BMC Infectious Diseases 2008, 8:161 http://www.biomedcentral.com/1471-2334/8/161
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risk. Quality assurance procedures will be followed along-
side mechanisms to ensure that all investigators can dem-
onstrate that they are qualified by training and experience
to fulfil their roles. Early termination of the study in
response to safety issues will be addressed via the Data
Monitoring Committee. Day to day management will be
undertaken via a trials management group composed of
the principal investigator and supporting staff. They will
meet on a regular basis to discuss study issues. Site moni-
toring will be directed by the sponsor according to the
study risk analysis.
Safety of investigators
The University, the Belfast and the South Eastern HSCTs
have Health and Safety Policies applicable to all employ-
ees. All personnel will adhere to any other Health and
Safety regulations relating to their area of work. The prin-
cipal investigator will ensure that all personnel have been
trained appropriately to undertake their specific tasks. As
the study fits closely to standard practice, additional risks
to the investigators will be minimal. The study team will
complete Good Clinical Practice and consent training
prior to start up.
Data Monitoring Committee (DMC)
A DMC will be convened by the Clinical Research Support
Centre and will meet every six months. An interim analy-
sis of efficacy is not planned although this can be
requested by the DMC as required. The DMC will function
primarily as a check for safety, reviewing adverse events.
Early termination of study in response to safety issues will
be addressed via the DMC. They will report any issues per-
taining to safety to the Chief Investigator. It will be the
responsibility of the principal investigator to inform the
sponsor who will take appropriate action to halt the trial
if concerns exist about participant safety.
Discussion
The impact of MRSA on morbidity and mortality has been
well documented, and TTO has been shown to eradicate
MRSA skin colonization. However, intervention studies
using preparations of TTO are not common. To our
knowledge, the proposed research is the first study to eval-
uate the effectiveness of TTO body wash in preventing col-
onisation with MRSA in a critically ill patient cohort. This
is particularly important because critically ill patients are
more vulnerable to infections and ICUs have the highest
incidence of MRSA colonization when compared with all
other wards. The provision of such a therapy may reduce
their chances of subsequently developing an MRSA infec-
tion.
The significance of this research can be considered from a
number of aspects pertaining to the patient. With its focus
on early identification and prevention, this study will
determine the efficacy of a new method for early identifi-
cation of MRSA, thus enabling prompt isolation to reduce
transmission to non-colonized patients. It will also deter-
mine whether a simple body wash prevents patients from
being colonised with MRSA. Finally, the research findings
will be of value to clinicians and health service managers
because they may facilitate more appropriate and efficient
use of health care resources to improve outcomes for crit-
ically ill patients.
If the study findings are positive and conclusive, this inter-
vention could be adopted widely – not only in ICUs, but
also within the primary and secondary public and private
health service institutions, residential and nursing homes.
The innovative aspects of the research are in their applica-
tion to this important group of vulnerable patients. This
research will also inform clinicians and health service pro-
viders about an intervention and method that serves the
needs of critically ill patients.
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